RIO DE JANEIRO, BRAZIL - The National Technical Committee on Biosafety - CTNBio has just approved the clinical protocol, submitted by Janssen, Johnson & Johnson's pharmaceutical arm, for conducting the phase 3 clinical trial (the last stage of a research) of the vaccine against the novel coronavirus in Brazil.
The third phase of clinical trials is expected to begin in September. The authorization request for the trial will also be analyzed by other bodies, such as ANVISA (National Health REgulatory Agency) and CONEP (National Research Ethics Committee).
Ad26.COV2.S, the name given to the vaccine developed by Johnson, is considered . . .